Hamed Gilzad Kohan

Hamed Gilzad Kohan

Auto-generated profile, based on publicly available information

Hamed Gilzad Kohan

Department of Pharmaceutical and Administrative Sciences, College of Pharmacy, Western New England University, Springfield, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
MSMarzieh Soheili
Marzieh Soheili
SNSherko Nasseri
Sherko Nasseri
MAMaryam Afraie
Maryam Afraie
SKSorour Khateri
Sorour Khateri
YMYousef Moradi
Yousef Moradi
HGHamed Gilzad-Kohan
Hamed Gilzad-Kohan
The World Health Organization, has declared the recent multiregional outbreak of monkeypox, a global public health emergency. Monkeypox is a zoonotic viral infection endemic to the west and central Africa. It belongs to the Poxviridae family, the Chordopoxvirinae subfamily, and the Orthopoxvirus genus. The Poxviridae family generally consists of complex, large, enveloped, and linear double-stranded DNA viruses. The initial clinical symptoms of monkeypox are often fever, severe headache, lymphadenopathy, myalgia, and fatigue. The skin lesions typically erupt within 1–3 days of the onset of fever. The rash tends to be more localized on the face and extremities than on the trunk. Monkeypox is often a self-limiting infection, and symptoms last from 2 to 4 weeks. It is isolated from various species, but the exact natural host is uncertain. Monkeypox is transmitted by close contact with infected humans or animals. Currently, no specific medication is available for monkeypox, and the existing therapeutics are the anti-viral agents approved for smallpox infection, including tecovirimat, cidofovir, and brincidofovir. Additionally, the U.S. Food and Drug Administration has approved Vaccinia Immune Globulin Intravenous for treating vaccination complications. It is diagnosed by PCR. There are currently two vaccines licensed by the U.S. Food and Drug Administration. According to the WHO guidance, the first-generation smallpox vaccines held in national reserves of some countries are not recommended as they do not meet the current safety and manufacturing standards. The interim guidance indicates that new and safer (second- and third generation) vaccines for smallpox, may be beneficial for monkeypox prevention, including JYNNEOS, which has been approved for the prevention of monkeypox. Human monkeypox was first reported in 1970. Since then, it has caused several outbreaks, mainly in central and west Africa. The first monkeypox outbreak outside of Africa occurred in the United States in 2003, linked to contact with infected pet prairie dogs. More recently (2018-2021), monkeypox cases have been reported in travelers from Nigeria to the United Kingdom, Israel, Singapore, and the US. Since May 2022, multiple monkeypox cases have been confirmed in several non-endemic countries, raising the concern of an emerging global pandemic. This review is an updated overview of our current state of knowledge regarding monkeypox virology, pathophysiology, clinical characteristics, epidemiology, vaccines, diagnosis, and treatment options.

4 July 2016 in Oncotarget
Verified
Journal Article
Open access
VMVandhana Muralidharan-Chari
Vandhana Muralidharan-Chari
HKHamed Gilzad Kohan
Hamed Gilzad Kohan
AAAlexandros G. Asimakopoulos
Alexandros G. Asimakopoulos
TSThangirala Sudha
Thangirala Sudha
SSStewart Sell
Stewart Sell
Shaker A MousaShaker A Mousa
Shaker A Mousa
Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells

19 May 2023 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
MSMarzieh Soheili
Marzieh Soheili
SKSorour Khateri
Sorour Khateri
FMFarhad Moradpour
Farhad Moradpour
PMPardis Mohammadzedeh
Pardis Mohammadzedeh
MZMostafa Zareie
Mostafa Zareie
YMYousef Moradi
Yousef Moradi
Objectives: This meta-analysis evaluated the Efficacy and Effectiveness of several COVID-19 vaccines, including AstraZeneca, Pfizer, Moderna, Bharat, and Johnson & Johnson, to better estimate their immunogenicity, benefits, or side effects. Methods: Studies reporting the Efficacy and Effectiveness of COVID-19 vaccines from November 2020 to April 2022 were included. The pooled Effectiveness/Efficacy with a 95% confidence interval (95% CI) with Metaprop order was calculated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed. Results: A total of twenty articles were included in this meta-analysis. After the first dose of the vaccine, the total effectiveness of all COVID-19 vaccines in our study was 71% (95% CI 0.65, 0.78). The total effectiveness of vaccines after the second dose was 91% (95% CI 0.88, 0.94)). The total efficacy of vaccines after the first and second doses was 81% (95% CI 0.70, 0.91) and 71% (95% CI 0.62, 0.79), respectively. The effectiveness of the Moderna vaccine after the first and second dose was the highest among other studied vaccines ((74% (95% CI, 0.65, 0.83) and 93% (95% CI, 0.89, 0.97), respectively). The highest first dose overall effectiveness of the studied vaccines was against the Gamma variant (74% (95% CI, 0.73, 0.75)), and the highest effectiveness after the second dose was observed against the Beta variant (96% (95% CI, 0.96, 0.96)). The Efficacy for AstraZeneca and Pfizer vaccines after the first dose was 78% (95% CI, 0.62, 0.95) and 84% (95% CI, 0.77, 0.92), respectively. The second dose Efficacy for AstraZeneca, Pfizer, and Bharat was 67% (95% CI, 0.54, 0.80), 93% (95% CI, 0.85, 1.00), and 71% (95% CI, 0.61, 0.82), respectively. The overall efficacy of first and second dose vaccination against the Alfa variant was 84% (95% CI, 0.84, 0.84) and 77% (95% CI, 0.57, 0.97), respectively, the highest among other variants. Conclusion: mRNA-based vaccines against COVID-19 showed the highest total efficacy and effectiveness than other vaccines. In general, administering the second dose produced a more reliable response and higher effectiveness than a single dose.

1 July 2012 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
AIAlyaa Ibrahim
Alyaa Ibrahim
MGMohammad H. Gilzad-Kohan
Mohammad H. Gilzad-Kohan
Ali Aghazadeh-HabashiAli Aghazadeh-Habashi
Ali Aghazadeh-Habashi
FJFakhreddin Jamali
Fakhreddin Jamali

1 February 2014 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
Ali Aghazadeh-HabashiAli Aghazadeh-Habashi
Ali Aghazadeh-Habashi
MKM.H. Gilzad Kohan
M.H. Gilzad Kohan
WAWaheed Asghar
Waheed Asghar
FJFakhreddin Jamali
Fakhreddin Jamali

15 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HKHamed Gilzad Kohan
Hamed Gilzad Kohan
KKKamaljit Kaur
Kamaljit Kaur
FJFakhreddin Jamali
Fakhreddin Jamali
The aim of this study was to synthesize a peptide prodrug of glucosamine (GlcN) with increased gut permeability through the gut peptide transporter 1 (PepT1). Glycine-Valine ester derivative of GlcN (GVG) was synthesised using solid phase synthesis followed by characterization and evaluation of its physicochemical and intestinal stability. In addition, GVG was evaluated for its ability to be biotransformed to GlcN in the liver homogenate. In vitro absorption of the new prodrug through everted rat gut was also assessed. GVG demonstrated significant and meaningful increased gut permeability as compared with GlcN. It showed favorable stability in the gut and a quick cleavage to GlcN after exposure to the liver homogenate. In conclusion, a novel prodrug of glucosamine with superior gut permeability compared to GlcN was developed and successfully tested in vitro.